<DOC>
	<DOCNO>NCT00963053</DOCNO>
	<brief_summary>The purpose study investigate effective VA111913 prevent menstrual pain woman primary dysmenorrhoea .</brief_summary>
	<brief_title>VA111913 Dysmenorrhoea Efficacy Safety Proof Concept</brief_title>
	<detailed_description>Dysmenorrhoea suffer 50 % 90 % woman child bear age . Up 30 % woman non-responsive currently prescribe therapy . As represent area unmet medical need . VA111913 inhibits vasopressin-induced contraction human myometrial strip human myometrial blood vessel vitro . By mechanism , anticipate pain dysmenorrhoea , condition myometrial tone contraction increase blood flow uterus decrease compare normal , may reduce . Subjects dose VA111913 TS placebo cross design two consecutive menstrual cycle . They dose maximum 6 day , begin 2 day onset menstruation . Subjects assess menstrual pain , bleed amount analgesia require treat symptom cycle</detailed_description>
	<mesh_term>Dysmenorrhea</mesh_term>
	<criteria>Women 18 35 year old Not pregnant History primary dysmenorrhoea Regular menstrual cycle Signed informed consent Known secondary dysmenorrhoea Concomitant use regular prescription non prescription medication herbal remedy Any clinically significant medical history active disease Participation another clinical study last 3 month Contraindication chosen rescue medication allergy constituent Other protocol define eligibility criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>dysmenorrhoea</keyword>
	<keyword>dysmenorrhea</keyword>
	<keyword>pain</keyword>
	<keyword>pre-emptive</keyword>
</DOC>